checkAd
    Startseite > Aktien > ZyVersa Therapeutics > Nachrichten
    ZyVersa Therapeutics Aktie
    4,9400
     
    USD
    +21,08 %
    +0,8600 USD
    Letzter Kurs 01.06.24 NYSE
    4,8100
     
    USD
    100 STK
    Geldkurs 31.05.24
    5,1600
     
    USD
    100 STK
    Briefkurs 31.05.24
    ISIN: US98987D3008 · SYM: ZVSA · USA

    Neueste Nachrichten

    ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock
    30.11.23 · globenewswire · ZyVersa Therapeutics
    ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results
    14.11.23 · globenewswire · ZyVersa Therapeutics
    ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
    09.11.23 · globenewswire · ZyVersa Therapeutics
    ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation
    06.11.23 · globenewswire · ZyVersa Therapeutics
    ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neur
    01.11.23 · globenewswire · ZyVersa Therapeutics
    ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease
    25.10.23 · globenewswire · ZyVersa Therapeutics
    ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function
    18.10.23 · globenewswire · ZyVersa Therapeutics
    ZyVersa Therapeutics Announces Peer-Reviewed Publication in Nature Reviews Nephrology Substantiating VAR 200’s Rationale for Mediating Transport of Cholesterol and Lipids Out of Kidney Cells to Attenuate Progression of Kidney Disease
    11.10.23 · globenewswire · ZyVersa Therapeutics
    ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues
    04.10.23 · globenewswire · ZyVersa Therapeutics
    ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous Diseases
    27.09.23 · globenewswire · ZyVersa Therapeutics
    ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues
    22.09.23 · globenewswire · ZyVersa Therapeutics
    ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100’s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases
    12.09.23 · globenewswire · ZyVersa Therapeutics